01 January 2000  
Founding Group

Founding Group

The Personalised Medicine meeting has unfortunately been postponed for April 2024 and we will be reimbursing fees to all registered delegates as soon as possible. We are working with the Founding Group to re-launch in 2025. We acknowledge that you may have questions about the postponed meeting and hope to be in a position to announce further information shortly.

Founding Group

We would like to thank our Founding Group, who have dedicated their expertise to creating the scientific programme for this meeting.

Constantine Stratakis

Professor Constantine A. Stratakis is an internationally known medical geneticist, endocrinologist, translational investigator and executive leader with a unique combination of skills and experience in science, healthcare, clinical trials, molecular research and genetics, policy, government regulations, and patient advocacy.

Prof. Stratakis served as the Chief Scientific Officer of ELPEN Pharmaceuticals in Athens (GR) and directed the efforts to build a new ELPEN Research Institute that is due to open in 2025, while he also runs human genetics and precision medicine at IMBB, FORTH, in Heraklion, GR.

Dr Gerald Raverot

Dr Raverot is a Professor in Endocrinology at Lyon 1 University and is head of the endocrine department and chief of the Reference Center of Rare Pituitary Disease and the Endocrine Department at Hospices Civils of Lyon participating in the European Reference Network on Rare Endocrine Conditions (Endo-ERN). He leads a research team dedicated to “Pathophysiology of pituitary tumour” at the INSERM U1052 Cancer Research Center of Lyon. He coordinated the European Society of Endocrinology guidelines on aggressive pituitary tumours and carcinoma.

His major research interests are pituitary tumor pathogenesis and identification of prognosis markers, allowing the development of potential new therapies. He is president-elected of the French Society of Endocrinology.

Professor Jonathan Wadsley

Professor Wadsley was appointed as a Consultant Clinical Oncologist at Weston Park Hospital, Sheffield, in 2004. His clinical interests are in thyroid cancer, neuroendocrine tumours and pancreatic/biliary tract cancers, with a particular interest in molecular radiotherapy.

His research mirrors these clinical interests, with a particular focus on thyroid cancer and neuroendocrine tumours. He is a member of the NCRI Thyroid Cancer Subgroup. He is the Clinical Director of the Sheffield Cancer Clinical Trials Centre, Cancer Specialty Lead for the Yorkshire and Humber Clinical Research Network and the NIHR National Specialty Lead for Radiotherapy and Imaging.

Professor Hermann L. Müller

Hermann L. Müller is a Professor of Pediatrics and head of the Department of Pediatrics and Pediatric Hematology/Onology, at University Children’s Hospital, Carl von Ossietzky University Oldenburg, Klinikum Oldenburg, Germany. He trained in general paediatrics at the Universities of Marburg and Würzburg, Germany. He completed a post-doctoral fellowship at Stanford University Medical Center (1991-1993, Prof. Dr Ron Rosenfeld) and then trained in pediatric oncology, haematology, endocrinology and diabetology at the Department of Pediatrics, University of Würzburg, Germany.

Since 1999, he has coordinated the German/European craniopharyngioma trials HIT-ENDO and KRANIOPHARYNGEOM 2000/2007, KRANIOPHARYNGEOM 2019 Registry, in which over 800 patients with childhood-onset craniopharyngioma from Germany, Austria and Switzerland have been recruited up to now.

Dr. Justo P. Castaño

Dr. Justo P. Castaño is Professor of Cell Biology at the University of Córdoba and Head of the Hormones and Cancer group at the Maimonides Institute of Biomedical Research of Córdoba (IMIBIC), Spain. His team investigates the cellular and molecular basis of neuroendocrine tumors (NETs), pancreatic adenocarcinoma, pituitary tumors and other cancers, exploring the emerging pathophysiologic and oncogenic role of alternative splicing and its related RNA controlling processes and associated signaling pathways, at the onco-endocrine translational interface.